Figure 7

Confirmation of oligosaccharide structure on rituximab after ENGase treatment. LC-MS analysis was performed on the following samples: (A) rituximab without ENGase treatment (B) treated with ORF1188 and (C) treated with Cordyceps ENGase. Note that the single peak derived from GlcNAc-fucose was observed in samples (B) and (C), but not in sample (A).